Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.
暂无分享,去创建一个
D. Ferry | L. Ciuffreda | J. Taieb | A. Sobrero | G. Aprile | Anne L. Thomas | R. Bordonaro | L. Frassineti | C. Zilocchi | E. Dochy | Y. Moore